Compare Adaptive Biotechnologies Corp (ADPT) vs Arqit Quantum Inc (ARQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Arqit Quantum Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.41 (market cap $4.04B), while Arqit Quantum Inc trades at $23.52 (market cap $424.79M). The key difference: Adaptive Biotechnologies Corp is far larger — about 9.5× Arqit Quantum Inc's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Arqit Quantum Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | ARQQ | |
|---|---|---|
Market Cap | $4.04B | $424.79M |
Sector | Health | Technology |
52-Week High | $25.45 | $58.27 |
52-Week Low | $12.30 | $11.78 |
Enterprise Value | $4.10B | $398.10M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.
The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.
ARQQ trades at $23.72, up 4.91% today, with a bullish technical signal from moving averages despite overbought RSI readings. The company shows explosive revenue growth but deep losses, with a P/S ratio of 352.9 reflecting high growth expectations. Recent news highlights a proof-of-concept with nLighten and strong H1 2026 revenue growth of 829% year-over-year, signaling commercial traction in quantum-safe encryption.
Outlook hinges on scaling revenue to offset high costs, with analyst sentiment split evenly between Buy and Hold. Key risks include sustained cash burn and competitive pressure, but government and telecom deals offer upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Arqit Quantum Inc
Arqit Quantum provides advanced cybersecurity software that uses symmetric key agreement technology. Its solutions protect networked devices and data against current and future cyber threats, including quantum attacks.
Read more on ARQQ →
